[go: up one dir, main page]

ID23014A - INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER - Google Patents

INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER

Info

Publication number
ID23014A
ID23014A IDW991597A ID991597A ID23014A ID 23014 A ID23014 A ID 23014A ID W991597 A IDW991597 A ID W991597A ID 991597 A ID991597 A ID 991597A ID 23014 A ID23014 A ID 23014A
Authority
ID
Indonesia
Prior art keywords
inhibitors
transferage
reducture
farnesil
combination
Prior art date
Application number
IDW991597A
Other languages
English (en)
Indonesian (id)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfrizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfrizer Products Inc filed Critical Pfrizer Products Inc
Publication of ID23014A publication Critical patent/ID23014A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW991597A 1997-06-16 1998-06-05 INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER ID23014A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
ID23014A true ID23014A (id) 1999-12-30

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991597A ID23014A (id) 1997-06-16 1998-06-05 INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER

Country Status (37)

Country Link
EP (1) EP0986387B1 (xx)
JP (1) JP3713051B2 (xx)
KR (1) KR100392573B1 (xx)
CN (1) CN1259868A (xx)
AP (1) AP9801261A0 (xx)
AR (1) AR013090A1 (xx)
AT (1) ATE235905T1 (xx)
BG (1) BG103946A (xx)
BR (1) BR9810616A (xx)
CA (1) CA2294399C (xx)
CO (1) CO4950607A1 (xx)
DE (1) DE69812933T2 (xx)
DK (1) DK0986387T3 (xx)
DZ (1) DZ2518A1 (xx)
EA (1) EA199901043A1 (xx)
ES (1) ES2196559T3 (xx)
GT (1) GT199800081A (xx)
HN (1) HN1998000091A (xx)
HR (1) HRP980328B1 (xx)
HU (1) HUP0004624A3 (xx)
ID (1) ID23014A (xx)
IL (1) IL132765A0 (xx)
IS (1) IS5259A (xx)
MA (1) MA24569A1 (xx)
NO (1) NO996206L (xx)
NZ (1) NZ500662A (xx)
OA (1) OA11231A (xx)
PA (1) PA8453601A1 (xx)
PE (1) PE82899A1 (xx)
PL (1) PL337651A1 (xx)
PT (1) PT986387E (xx)
SK (1) SK169699A3 (xx)
TN (1) TNSN98088A1 (xx)
TR (1) TR199903074T2 (xx)
UA (1) UA57081C2 (xx)
WO (1) WO1998057633A1 (xx)
ZA (1) ZA985182B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058505A2 (en) * 1998-05-12 1999-11-18 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
WO2000016778A1 (en) * 1998-09-24 2000-03-30 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1395577A1 (en) 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

Also Published As

Publication number Publication date
KR100392573B1 (ko) 2003-07-23
ES2196559T3 (es) 2003-12-16
AP9801261A0 (en) 1999-12-11
JP3713051B2 (ja) 2005-11-02
IS5259A (is) 1999-11-19
OA11231A (en) 2003-05-26
SK169699A3 (en) 2000-06-12
PT986387E (pt) 2003-06-30
CA2294399A1 (en) 1998-12-23
EP0986387A1 (en) 2000-03-22
NO996206D0 (no) 1999-12-15
MA24569A1 (fr) 1998-12-31
DZ2518A1 (fr) 2003-02-01
NZ500662A (en) 2001-10-26
DK0986387T3 (da) 2003-07-14
JP2000513031A (ja) 2000-10-03
EA199901043A1 (ru) 2000-06-26
CA2294399C (en) 2004-03-16
DE69812933T2 (de) 2003-11-06
ZA985182B (en) 1999-12-17
NO996206L (no) 2000-02-15
PA8453601A1 (es) 2000-05-24
AR013090A1 (es) 2000-12-13
PL337651A1 (en) 2000-08-28
HRP980328A2 (en) 1999-04-30
BG103946A (bg) 2000-07-31
GT199800081A (es) 1999-12-07
PE82899A1 (es) 1999-08-26
UA57081C2 (uk) 2003-06-16
HN1998000091A (es) 1999-09-29
IL132765A0 (en) 2001-03-19
AU7445998A (en) 1999-01-04
KR20010013839A (ko) 2001-02-26
WO1998057633A1 (en) 1998-12-23
HRP980328B1 (en) 2002-06-30
AU724676B2 (en) 2000-09-28
BR9810616A (pt) 2000-09-12
ATE235905T1 (de) 2003-04-15
HUP0004624A3 (en) 2002-11-28
HUP0004624A2 (hu) 2001-10-28
EP0986387B1 (en) 2003-04-02
TNSN98088A1 (fr) 2005-03-15
DE69812933D1 (de) 2003-05-08
CO4950607A1 (es) 2000-09-01
CN1259868A (zh) 2000-07-12
TR199903074T2 (xx) 2000-05-22

Similar Documents

Publication Publication Date Title
FI963597L (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
NO962269D0 (no) Enzyminhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
NO942064D0 (no) yminhibitorer
ID19198A (id) Inhibitor metaloprotease heterosiklik
FI980038L (fi) Tuumorinekroositekijän alfa inhibiittoreita
DK1105413T3 (da) Hepatitis C-inhibitor-tripeptider
ID18416A (id) Inhibitor metaloprotease diheterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
ID24076A (id) Inhibitor-inhibitor protein transferase farnesil
FI941767L (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO996578D0 (no) Urokinase-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
FI974618L (fi) Kahden- ja kolmenarvoiset pienimolekyyliset selektiininestäjät
FI961697L (fi) 16-substituoidut-4-atsa-androstaani 5alfa-reduktaasi-isotsyymi-1-inhibiittorit
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
ID23014A (id) INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER
DE59806475D1 (de) Urokinase-inhibitoren
FI971156A0 (fi) 5alfa-reduktaasi-inhibiittoreita
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20005680D0 (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
FI973929A0 (fi) WOF inhibitor
MA24877A1 (fr) INHIBITEURS DE PROTéASES